Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying cryoglobulinemic vasculitis CV, a rare and serious immune system disorder that causes inflammation of blood vessels and can affect the skin, joints, kidneys, nerves, and other organs. This trial focuses on patients with active non-infectious CV who have not responded well to or cannot tolerate the current standard treatment Rituximab. The study aims to evaluate the safety and effectiveness of a different antibody treatment called Obinutuzumab in these patients. Participants will receive Obinutuzumab through an intravenous infusion at a dose of 1000 milligrams given at the start of the study and again two weeks later. This treatment is being assessed as a potential new option for CV patients who have limited choices due to resistance or intolerance to Rituximab. The trial is conducted as a single-arm study, meaning all participants receive Obinutuzumab, and it is designed as a phase 2 proof-of-concept study. During the study, participants will be monitored regularly for clinical response, side effects, and changes in disease activity using various clinical and laboratory tests over several months. Key outcomes include the rate of complete clinical response at 6 months, safety events up to 48 weeks, and longer-term measures of disease relapse and survival up to almost three years. Participants will undergo assessments including physical exams, laboratory tests, and disease activity scores to track progress and safety throughout the trial.
Actively Recruiting
Radiotherapy for breast cancer can cause arm lymphedema, which is swelling that may lead to long-term discomfort and affect quality of life. This clinical trial is designed to assess whether an artificial intelligence AI tool that predicts individual risk of arm lymphedema after radiotherapy can help patients and doctors make better treatment decisions. The trial includes women aged 18 or older with breast cancer needing regional lymph node radiotherapy after surgery, regardless of hormone receptor or tumor status. Participants will be randomly assigned to two groups. In the experimental group, patients and physicians will see the AI-predicted risk through a web app that explains risk factors and suggests measures like compression sleeves. In the control group, this risk information will not be shared. Both groups receive the same radiotherapy treatment they would normally have, with no changes to dose or technique. The AI tool is evaluated only for its impact on decision-making and outcomes. Throughout two years, participants will have regular check-ups to track treatment choices, side effects, shoulder movement, breast appearance, quality of life, and the accuracy of the AI tools predictions. Researchers will also monitor how well patients follow recommendations for using compression sleeves, as well as cancer recurrence and survival. Questionnaires and clinical exams will be conducted at baseline, during treatment, and at multiple follow-up points to gather detailed information.
Actively Recruiting
This research aims to find out how common cardiac amyloidosis is among older adults aged 80 years and above who have been hospitalized for heart failure and show thickening of the hearts left ventricle. The study is observational and conducted across multiple geriatric and cardiology centers. It focuses on patients who have experienced heart failure with specific heart muscle changes seen on echocardiography. Participants will be recruited over 24 months and followed for 12 months. At the start, researchers will collect medical history, demographic information, clinical data, frailty status, biological and genetic tests, and echocardiogram results. Bone scans using specific tracers will be performed during or after hospital stays to check for heart muscle involvement. Follow-up will include phone calls every three months to track hospitalizations, care facility admissions, and survival. During the study, participants will have regular assessments including frailty scales, cognitive tests, and questionnaires related to neuropathic pain and independence in daily activities. Researchers will evaluate bone scan results to detect amyloidosis and measure other health and functional outcomes. The study aims to provide a clearer picture of cardiac amyloidosis prevalence and patient condition over one year.
Actively Recruiting
Researchers are studying anticoagulation methods for the extracorporeal circuit ECC used during Renal Replacement Therapy RRT in patients with acute kidney injury. The study compares two approaches regional citrate anticoagulation RCA, which uses citrate infusion to reduce ionized calcium and prevent clotting, and a citrate-free method that lowers ionized calcium through a calcium-free dialysate and hemofilter performance. This comparison aims to assess the efficiency and safety of avoiding citrate infusion, which can cause metabolic side effects. Participants will undergo intermittent RRT using Sustained Low-Efficiency Dialysis SLED with two treatment periods in a crossover design. One period involves regional anticoagulation using citrate-free decalcification, and the other uses regional citrate anticoagulation with 4% citrate infusion. The order of treatments is randomized, allowing each participant to receive both interventions sequentially. During each RRT session, researchers will measure plasma urea levels over 8 hours and monitor concentrations of ionized calcium and magnesium at specified intervals. Heart rate and blood pressure will be recorded frequently throughout the sessions. Additionally, occurrences of circuit losses and catheter thrombosis will be tracked. These evaluations help compare the anticoagulation methods effectiveness and safety over the study period, which concludes in November 2025.
Actively Recruiting
Small Bowel Obstruction SBO is a common emergency condition diagnosed mainly by abdominal CT scans, which help guide treatment including medical care or surgery. However, CT scans expose patients to radiation, increase costs, and extend emergency department stays. Researchers are evaluating the use of Point of Care Ultrasound POCUS combined with clinical judgment Gestalt probability to safely exclude SBO in patients with low or moderate risk, potentially reducing the need for CT scans. In this observational study, trained emergency physicians will perform POCUS on patients with suspected SBO who have low or moderate Gestalt clinical probability. The ultrasound will look for signs like dilated, fluid-filled intestinal loops in different abdominal zones. After POCUS, all patients will receive a CT scan to confirm SBO presence or absence, serving as the gold standard. The main goal is to assess how well POCUS can rule out SBO in this specific patient group. Participants will be followed for 28 days, with data collected on the accuracy of POCUS compared to CT, time from ultrasound to CT results, and any false positives or negatives. Physicians will also evaluate the ease and usefulness of POCUS. This study aims to show that POCUS can reduce unnecessary CT scans, lowering radiation exposure, costs, emergency department length of stay, and workload for radiologists.
Actively Recruiting
Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to the standard care for hospitalized adult patients with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, and double-blind trial aims to compare trimodulin plus standard care against placebo plus standard care. The study also includes assessments of trimodulins detailed pharmacokinetic and pharmacodynamic properties. Participants are randomly assigned in a 11 ratio to receive either trimodulin or a placebo, both given intravenously once daily for five consecutive days alongside standard care. Following treatment, participants enter a follow-up phase lasting up to 23 days, with an end-of-follow-up visit or phone call on day 29. For those still hospitalized after day 29, extended follow-up continues until discharge or day 90, and a closing visit or call is conducted around day 91. During the study, participants will undergo multiple assessments including evaluation of mortality rates up to 28 and 90 days, clinical cure rates, organ failure scores, ventilator use, oxygen supply, ICU and hospital stays, readmission rates, adverse events, and changes in vital signs and laboratory parameters. Safety monitoring includes electrocardiograms and tracking of adverse events throughout the treatment and follow-up periods. The total participation duration can extend up to approximately three months depending on hospital discharge timing.
Actively Recruiting
Researchers are evaluating the effectiveness of cotrimoxazole compared to standard antibiotic therapy for treating ventilator-associated pneumonia VAP caused by Enterobacteriaceae in adult patients in intensive care units ICU. This multicenter randomized trial aims to determine if cotrimoxazole is not inferior to the best standard care in terms of survival 28 days after treatment begins. Patients with confirmed VAP and susceptibility to cotrimoxazole are included, with specific attention to those with or without septic shock and COVID-19 pneumonia. Participants are randomly assigned to receive either cotrimoxazole or standard antibiotic treatment, such as beta-lactams or fluoroquinolones, for a total of 7 days including initial empiric treatment. The antibiotic dosing and administration are adjusted based on current ICU recommendations. The treatment period can last up to 28 days or until death or ICU discharge if earlier. The study is not blinded due to variable therapies in the control group. During the study, patients are monitored daily until death, ICU discharge, or day 28 for vital signs, antibiotic use, new infections, and Clostridium difficile infection. Clinical and radiological evaluations occur at day 7, and weekly screening for multidrug-resistant bacteria is performed. Survival status is followed up to 90 days through phone or hospital interview. An independent committee reviews clinical and radiological outcomes without knowledge of treatment assignment to ensure unbiased assessment.
Actively Recruiting
Researchers are evaluating the impact of a temporary accommodation program called HTSH on elderly patients length of stay in hospital services. This observational, multicenter study involves elderly patients discharged from hospitals in the Ile-de-France region who require short-term accommodation in nursing homes or long-term care units. The study aims to assess how this program supports medical and social care and influences decisions about returning home after hospitalization. The study includes a prospective group of 258 subjects and a retrospective group using data from 2021 and 2022. Temporary accommodation beds are provided in dedicated units with specialized staff, physically grouped within establishments supported by the Regional Health Agency. The study compares hospital stay lengths before and after the programs implementation to evaluate its efficiency. Participants will be observed over 24 months with data collected on hospital stay length, patient pathways, profiles, discharge outcomes, quality of life, and caregiver benefits. Medical records and social evaluations are reviewed, and caregivers and professionals involved in the HTSH circuit may also participate. This non-interventional study monitors outcomes without changing usual care, with no specified maximum age and no healthy volunteers included.
Actively Recruiting
Older adults face a high risk of acute respiratory infections, which lead to hospitalization, death, and loss of independence globally. Reduced immune function with age and environmental exposures increase vulnerability and lower vaccine effectiveness. This international study evaluates the impact of hospitalizations caused by respiratory viruses such as influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus on loss of autonomy in people aged 60 and older to guide better prevention and vaccination approaches. The study observes individuals hospitalized with confirmed infections from these respiratory viruses. There are no experimental treatments instead, researchers monitor the patients over time to assess changes in their ability to perform daily activities. Functional dependency is measured at hospital admission, discharge, and at 3 and 6 months after discharge. The study also tracks health outcomes like medical complications, length of hospital stay, ICU admission, readmissions, new medications, and living situation changes. Participants will undergo evaluations of their daily living skills using standardized scores at multiple time points during and after hospitalization. Data on demographics, vaccination status, and comorbidities are collected at baseline. Follow-up phone assessments at 3 and 6 months help capture recovery and long-term effects. The study aims to deepen understanding of how respiratory infections affect older adults independence and support strategies for healthier aging.
Actively Recruiting
Ventilator-associated pneumonia VAP is a common hospital-acquired infection in intensive care units linked to longer use of mechanical ventilation and the overuse of antibiotics. This trial evaluates two strategies for starting antibiotic treatment in patients suspected of having non-severe VAP immediate antibiotic therapy after sampling versus waiting for bacteriological confirmation before starting antibiotics. The study aims to understand the impact of these approaches on patient outcomes and antibiotic resistance. Participants are randomly assigned to one of two groups the usual care group, where antibiotics begin within one hour of randomization based on clinical judgment, or the conservative strategy group, where antibiotics are delayed until microbiological results confirm infection. If cultures are negative, antibiotics are stopped or not started. If confirmed, antibiotics targeting the identified bacteria are given for seven days. Treatment decisions consider local protocols and resistance risks. During the study, participants are closely monitored for 28 days to assess survival and duration of mechanical ventilation. Various clinical scores and infection-related outcomes are recorded, including organ failure, infection clearance, antibiotic use, and hospital stay length. The study also evaluates antibiotic resistance and adverse effects. Data are collected from randomization through ICU and hospital discharge, with a primary focus on death or ventilation status at day 28.
1-10 of 20
1